Crescita Therapeutics (TSX:CTX) EV-to-EBIT : -0.26 (As of May. 12, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Crescita Therapeutics's Enterprise Value is C$0.37 Mil. Crescita Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.45 Mil. Therefore, Crescita Therapeutics's EV-to-EBIT for today is -0.26.

The historical rank and industry rank for Crescita Therapeutics's EV-to-EBIT or its related term are showing as below:

TSX:CTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -43.38 Med: 0.07 Max: 18.23
Current: -0.26

During the past 10 years, the highest EV-to-EBIT of Crescita Therapeutics was 18.23. The lowest was -43.38. And the median was 0.07.

TSX:CTX's EV-to-EBIT is ranked worse than
100% of 669 companies
in the Drug Manufacturers industry
Industry Median: 17.95 vs TSX:CTX: -0.26

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Crescita Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$1.65 Mil. Crescita Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.45 Mil. Crescita Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -87.73%.

Crescita Therapeutics EV-to-EBIT Historical Data

The historical data trend for Crescita Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics EV-to-EBIT Chart

Crescita Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

3.00

1.82

-6.70

12.09

-1.14

Crescita Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															12.09	5.00	6.18	-5.05	-1.14

Competitive Comparison of Crescita Therapeutics's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescita Therapeutics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's EV-to-EBIT falls into.

Crescita Therapeutics EV-to-EBIT Calculation

Crescita Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.370	/	-1.445
	=	-0.26

Crescita Therapeutics's current Enterprise Value is C$0.37 Mil.
Crescita Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.45 Mil.

Crescita Therapeutics (TSX:CTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Crescita Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-1.445	/	1.647146
	=	-87.73 %

Crescita Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$1.65 Mil.
Crescita Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.45 Mil.

Crescita Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (TSX:CTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (TSX:CTX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CRRTF:USA

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.

Crescita Therapeutics (TSX:CTX) Headlines

No Headlines